INS and type 1 diabetes mellitus: Despite the observed increase in the number of international units of insulin analogues dispensed, health technology assessments conducted by the National Technology Implementation Commission (Comissão Nacional de Incorporação de Tecnologias-Conitec) for SUS in 2013, recommended against the inclusion of the fast-acting insulin analogues (lispro, aspart and glulisine) for the treatment of type 1 diabetes [21] and the long-acting insulin analogues (detemir and glargine) for the treatment of types 1 and 2 diabetes patients [22].